• 1
    Lee HS, Kim JS, Choi IJ, Chung JW, Park JH, Kim CY. The safety and efficacy of transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstruction: a prospective controlled study. Cancer 1997; 79: 208794.
  • 2
    Yamakado K, Tanaka N, Nakatsuka A, Matsumura K, Takase K, Takeda K. Clinical efficacy of portal vein stent placement in patients with hepatocellular carcinoma invading the main portal vein. J Hepatol 1999; 30: 6608.
  • 3
    The Cancer of the Liver Italian Program (CLIP) investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology 1998; 28: 7515.
  • 4
    Ando E, Yamashita F, Tanaka M, Tanikawa K. A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein. Cancer 1997; 79: 18906.
  • 5
    Furuse J, Iwasaki M, Yoshino M, Konishi M, Kawano N, Kinoshita T, et al. Hepatocellular carcinoma with portal vein tumor thrombus: embolization of arterioportal shunts. Radiology 1997; 204: 78790.
  • 6
    Asahara T, Itamoto T, Katayama K, Nakahara H, Hino H, Yano M, et al. Hepatic resection with tumor thrombectomy for hepatocellular carcinoma with tumor thrombi in the major vasculature. Hepatogastroenterology 1999; 46: 18629.
  • 7
    Chen SC, Hsieh MY, Chuang WL, Wang LY, Chang WY. Development of portal vein invasion and its outcome in hepatocellular carcinoma treated by transcatheter arterial chemo-embolization. J Gastroenterol Hepatol 1994; 9: 16.
  • 8
    Tanaka A, Morimoto T, Yamaoka Y. Implications of surgical treatment for advanced hepatocellular carcinoma with tumor thrombi in the portal vein. Hepatogastroenterology 1996; 43: 63743.
  • 9
    Fujii T, Takayasu K, Muramatsu Y, Moriyama N, Wakao F, Kosuge T, et al. Transcatheter arterial embolization for hepatocellular carcinoma with portal vein thrombosis. J Gastroenterol Hepatol 1995; 10: 23740.
  • 10
    Fujii T, Takayasu K, Muramatsu Y, Moriyama N, Wakao F, Kosuge T, et al. Hepatocellular carcinoma with portal tumor thrombus: analysis of factors determining prognosis. Jpn J Clin Oncol 1993; 23: 1059.
  • 11
    Tanaka A, Morimoto T, Ozaki N, Ikai I, Yamamoto Y, Tsunekawa S, et al. Extension of surgical indications for advanced hepatocellular carcinoma: is it possible to prolong life span or improve quality of life? Hepatogastroenterology 1996; 43: 117281.
  • 12
    Yamaoka Y, Kumada K, Ino K, Takayasu T, Shimahara Y, Mori K, et al. Liver resection for hepatocellular carcinoma (HCC) with direct removal of tumor thrombi in the main portal vein. World J Surg 1992; 16: 11726.
  • 13
    Lin DY, Lin SM, Liaw YF. Non-surgical treatment of hepatocellular carcinoma. J Gastroenterol Hepatol 1997; 12: S31928.
  • 14
    Stehlin JS Jr., de Ipolyi PD, Greeff PJ, McGaff CJ Jr., Davis BR, McNary L. Treatment of cancer of the liver: twenty years experience with infusion and resection in 414 patients. Ann Surg 1988;208: 235.
  • 15
    Doci R, Bignami P, Bozzetti F, Bonfanti G, Audisio R, Colombo M, et al. Intrahepatic chemotherapy for unresectable hepatocellular carcinoma. Cancer 1988; 61: 19837.
  • 16
    Miyamoto A, Umeshita K, Sakon M, Nagano H, Eguchi H, Kishimoto S, et al. A case of advanced hepatocellular carcinoma with lung metastasis, successfully treated by a combination therapy with interferon-α and UFT, an oral antineoplastic agent combining tegafur and uracil. J Gastroenterol Hepatol 2000; 15: 144751.
  • 17
    Toyoda H, Nakano S, Kumada T, Takeda I, Sugiyama K, Osada T, et al. The efficacy of continuous local arterial infusion of 5-fluorouracil and cisplatin through an implanted reservoir for severe advanced hepatocellular carcinoma. Oncology 1995; 52: 2959.
  • 18
    Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 64955.
  • 19
    Urabe T, Kaneko S, Matsushita E, Unoura M, Kobayashi K. Clinical pilot study of intrahepatic arterial chemotherapy with methotrexate, 5-fluorouracil, cisplatin and subcutaneous interferon-alpha-2b for patients with locally advanced hepatocellular carcinoma. Oncology 1998; 55: 3947.
  • 20
    Kajanti M, Pyrhonen S, Mantyla M, Rissanen P. Intra-arterial and intravenous use of 4′ epidoxorubicin combined with 5-fluorouracil in primary hepatocellular carcinoma: a randomized comparison. Am J Clin Oncol 1992; 15: 3740.
  • 21
    Minoyama A, Yoshikawa M, Ebara M, Saisho H, Sugiura N, Ohto M. Study of repeated arterial infusion chemotherapy with a subcutaneously implanted reservoir for advanced hepatocellular carcinoma. J Gastroenterol 1995; 30: 35666.
  • 22
    Nair PV, Tong MJ, Kempf R, Co R, Lee SD, Venturi CL. Clinical, serologic, and immunologic effects of human leukocyte interferon in HBsAg-positive primary hepatocellular carcinoma. Cancer 1985; 56: 101822.
  • 23
    Sachs E, Di Bisceglie AM, Dusheiko GM, Song E, Lyons SF, Schoub BD, et al. Treatment of hepatocellular carcinoma with recombinant leucocyte interferon: a pilot study. Br J Cancer 1985; 52: 1059.
  • 24
    The Gastrointestinal Tumor Study Group. A prospective trial of recombinant human interferon alpha 2B in previously untreated patients with hepatocellular carcinoma. Cancer 1990; 66: 1359.
  • 25
    Llovet JM, Sala M, Castells L, Suarez Y, Vilana R, Bianchi L, et al. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 2000; 31: 548.
  • 26
    Lai CL, Lau JY, Wu PC, Ngan H, Chung HT, Mitchell SJ, et al. Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial. Hepatology 1993; 17: 38994.
  • 27
    Yamanaka N, Takada M, Tanaka T, Yamanaka J, Yasui C, Ando T, et al. Viral serostatus and coexisting inflammatory activity affect metachronous carcinogenesis after hepatectomy for hepatocellular carcinoma. A further report. J Gastroenterol 2000;35: 20613.
  • 28
    Creagan ET, Long HJ, Frytak S, Moertel CG. Recombinant leukocyte A interferon with doxorubicin: a phase I study in advanced solid neoplasms and implications for hepatocellular carcinoma. Cancer 1988; 61: 1922.
  • 29
    Kardinal CG, Moertel CG, Wieand HS, Schutt AJ, O'Connell MJ, Wright K, et al. Combined doxorubicin and alpha-interferon therapy of advanced hepatocellular carcinoma. Cancer 1993; 71: 218790.
  • 30
    Feun LG, Savaraj N, Hung S, Reddy R, Jeffers L, Benedetto P, et al. A phase II trial of recombinant leukocyte interferon plus doxorubicin in patients with hepatocellular carcinoma. Am J Clin Oncol 1994; 17: 3935.
  • 31
    Leung TW, Patt YZ, Lau WY, Ho SK, Yu SC, Chan AT, et al. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res 1999; 5: 167681.
  • 32
    Chung YH, Song IH, Song BC, Lee GC, Koh MS, Yoon HK, et al. Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-α for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis. Cancer 2000; 88: 198691.
  • 33
    Sangfelt O, Erickson S, Castro J, Heiden T, Gustafsson A, Einhorn S, et al. Molecular mechanisms underlying interferon-alpha-induced G0/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins. Oncogene 1999; 18: 2798810.
  • 34
    Yano H, Iemura A, Haramaki M, Ogasawara S, Takayama A, Akiba J, et al. Interferon alfa receptor expression and growth inhibition by interferon alfa in human liver cancer cell lines. Hepatology 1999; 29: 170817.
  • 35
    Lindahl P, Leary R, Gresser I. Enhancement by interferon of the specific cytotoxicity of sensitized lymphocytes. Proc Natl Acad Sci USA 1972; 69: 7215.
  • 36
    Trinchieri G, Santoli D, Koprowski H. Spontaneous cell-mediated cytotoxicity in humans; role of interferon and immunoglobulins. J Immunol 1978; 120: 184955.
  • 37
    Horowitz RW, Heerdt BG, Hu X, Schwartz EL, Wadler S. Combination therapy with 5-fluorouracil and IFN-α2a induces a nonrandom increase in DNA fragments of less than 3 megabases in HT29 colon carcinoma cells. Clin Cancer Res 1997; 3: 131722.
  • 38
    Sabaawy HE, Farley T, Ahmed T, Feldman E, Abraham NG. Synergistic effects of retrovirus IFN-alpha gene transfer and 5-FU on apoptosis of colon cancer cells. Acta Haematol 1999; 101: 828.
  • 39
    Folkman J, Ingber D. Inhibition of angiogenesis. Semin Cancer Biol 1992; 3: 8996.
  • 40
    Slaton JW, Perrotte P, Inoue K, Dinney CP, Fidler IJ. Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res 1999; 5: 272634.
  • 41
    Dinney CP, Bielenberg DR, Perrotte P, Reich R, Eve BY, Bucana CD, et al. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. Cancer Res 1998; 58: 80814.
  • 42
    Wadler S, Schwartz EL. Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res 1990; 50: 347386.
  • 43
    Elias L, Sandoval JM. Interferon effects upon fluorouracil metabolism by HL-60 cells. Biochem Biophys Res Commun 1989; 163: 86774.
  • 44
    Schwartz EL, Hoffman M, O'Connor CJ, Wadler S. Stimulation of 5-fluorouracil metabolic activation by interferon-alpha in human colon carcinoma cells. Biochem Biophys Res Commun 1992; 182: 12329.
  • 45
    Patt YZ, Yoffe B, Charnsangavej C, Pazdur R, Fischer H, Cleary K, et al. Low serum alpha-fetoprotein level in patients with hepatocellular carcinoma as a predictor of response to 5-FU and interferon-alpha-2b. Cancer 1993; 72: 257482.